Sotera Health Up 30% This Past Year, so Why Did One Fund Sell $4 Million in Shares?

2 weeks ago 11

Jonathan Ponciano, The Motley Fool

Mon, March 2, 2026 astatine 8:11 AM CST 4 min read

On February 17, 2026, Ananym Capital Management disclosed the merchantability of 217,684 shares of Sotera Health (NASDAQ:SHC), with an estimated transaction worth of $3.60 cardinal based connected quarterly mean pricing.

According to an SEC filing dated February 17, 2026, Ananym Capital Management reduced its presumption successful Sotera Health by 217,684 shares. The estimated worth of the sale, based connected the filing quarter’s mean price, was $3.60 million. The fund’s quarter-end presumption successful the institution shifted by $1.15 million, a fig that includes some trading enactment and changes successful Sotera Health’s stock terms during the period.

The simplification lowered Sotera Health’s involvement to 8.65% of Ananym’s 13F reportable AUM arsenic of December 31, 2025.
Top holdings aft the filing:
- NYSE:VAC: $42.51 cardinal (17.5% of AUM)
- NASDAQ:HSIC: $41.35 cardinal (17.0% of AUM)
- NASDAQ:BKR: $36.61 cardinal (15.1% of AUM)
- NASDAQ:SCHL: $35.85 cardinal (14.7% of AUM)
- NASDAQ:LKQ: $33.52 cardinal (13.8% of AUM)
As of February 17, 2026, shares of Sotera Health were priced astatine $17.09, up astir 30% implicit the past twelvemonth and outperforming the S&P 500 by 14.86 percent points.

Metric

Value

Revenue (TTM)	$1.16 billion
Net income (TTM)	$77.95 million
Price (as of marketplace adjacent 2/17/26)	$17.09
One-year terms change	26.59%

Sotera Health provides sterilization services (gamma, electron beam, and EO processing), laboratory testing, and advisory services for aesculapian device, pharmaceutical, and nutrient industries.
The institution serves aesculapian instrumentality manufacturers, pharmaceutical companies, and food/agricultural businesses crossed the United States, Canada, Europe, and planetary markets.
It operates with a diversified portfolio of services to code regulatory and information requirements for a planetary lawsuit base.

Sotera Health is simply a starring supplier of sterilization and laboratory investigating solutions, supporting captious sectors specified arsenic healthcare and pharmaceuticals. The institution leverages its standard and method expertise to service companies requiring reliable sterilization and compliance services worldwide.

When a antiaircraft healthcare services sanction inactive commands astir 9% of a portfolio aft a trim, it tells you condemnation remains intact. In different words, the humble simplification present looks much similar hazard absorption aft a beardown tally than a nonaccomplishment of religion successful the concern model.

Sotera conscionable delivered its 20th consecutive twelvemonth of gross growth, with 2025 nett revenues rising astir 6% to $1.16 cardinal and adjusted EBITDA climbing 8% to $594 million. Net income astir doubled twelvemonth implicit twelvemonth to $78 million, and absorption guided for different 5% to 6.5% gross summation successful 2026 alongside adjusted EBITDA maturation of 5.5% to 7.0%.

To beryllium clear, this is not a speculative biotech. Sotera operates mission-critical sterilization and investigating infrastructure that aesculapian instrumentality and pharma companies cannot easy replace. Cash travel improved, leverage fell to 3.2 times adjusted EBITDA, and liquidity strengthened.

Within a portfolio that besides leans into cyclical and concern names, keeping Sotera arsenic a apical allocation preserves vulnerability to steady, regulated demand. Long-term investors should absorption little connected a $3.6 cardinal commercialized and much connected a concern compounding gross for 2 decades successful an manufacture wherever reliability is precise important.

Read Entire Article